Human Genome Sciences' ABthrax delayed by FDA complete response
This article was originally published in Scrip
Executive Summary
The US FDA has issued a complete response letter for Human Genome Sciences' ABthrax (raxibacumab injection), seeking additional information about the investigational treatment for inhalational anthrax.